Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP380920.RAzA5jT88xIvPhramMyw-ph-n3ZsrzkNfxBmVOdgLlzu4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP380920.RAzA5jT88xIvPhramMyw-ph-n3ZsrzkNfxBmVOdgLlzu4130_assertion type Assertion NP380920.RAzA5jT88xIvPhramMyw-ph-n3ZsrzkNfxBmVOdgLlzu4130_head.
- NP380920.RAzA5jT88xIvPhramMyw-ph-n3ZsrzkNfxBmVOdgLlzu4130_assertion description "[Our data confirm that downregulating the ErbB3-mediated signals with the use of anti-ErbB3 monoclonal antibodies is both feasible and relevant for therapeutic purposes and provides new opportunities for novel anti-ErbB3 combinatory strategies for cancer treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP380920.RAzA5jT88xIvPhramMyw-ph-n3ZsrzkNfxBmVOdgLlzu4130_provenance.
- NP380920.RAzA5jT88xIvPhramMyw-ph-n3ZsrzkNfxBmVOdgLlzu4130_assertion evidence source_evidence_literature NP380920.RAzA5jT88xIvPhramMyw-ph-n3ZsrzkNfxBmVOdgLlzu4130_provenance.
- NP380920.RAzA5jT88xIvPhramMyw-ph-n3ZsrzkNfxBmVOdgLlzu4130_assertion SIO_000772 22213458 NP380920.RAzA5jT88xIvPhramMyw-ph-n3ZsrzkNfxBmVOdgLlzu4130_provenance.
- NP380920.RAzA5jT88xIvPhramMyw-ph-n3ZsrzkNfxBmVOdgLlzu4130_assertion wasDerivedFrom befree-20150227 NP380920.RAzA5jT88xIvPhramMyw-ph-n3ZsrzkNfxBmVOdgLlzu4130_provenance.
- NP380920.RAzA5jT88xIvPhramMyw-ph-n3ZsrzkNfxBmVOdgLlzu4130_assertion wasGeneratedBy ECO_0000203 NP380920.RAzA5jT88xIvPhramMyw-ph-n3ZsrzkNfxBmVOdgLlzu4130_provenance.